StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Fasenra (benralizumab) — Europe product sales by Quarter

Fasenra (benralizumab) — Europe product sales ($M) ($M)

QuarterlyAnnual

AstraZeneca Fasenra (benralizumab) — Europe product sales: $129M in Q2 2026, up 3.2% from a year earlier.

Latest, Q2 2026
129
Period ended Jun 30, 2026
Change on a year earlier
+3.2%
125 in Q2 2025
History
23 quarters
Since Q4 2020
Sources
23
Documents cited below

Where the Q2 2026 figure comes from

“|| Fasenra | 570 | | 14 | | 13 | | 338 | | 10 | | 46 | | 81 | | 75 | | 129 | | 3 | | ( 1 ) | | 57 | | 29 | | 34”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K / 20-F Product Sales Table.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedFasenra (benralizumab) — Europe product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026129+3.2%Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 2026129+25.2%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 2025131+19.1%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 2025122+19.6%Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 2025125+26.3%Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 2025103+10.8%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 2024110+18.3%Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 2024102+18.6%Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 202499+11.2%Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 202493+5.7%Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 202393+22.4%Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 202386+11.7%Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 202389+14.1%Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 202388+17.3%Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 202276+1.3%Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 202277+2.7%Form 6-K FY2022Q3 Earnings Release ↗

Breakdown

What makes up fasenra (benralizumab) — Europe product sales

Cite this data

StockData. (2026). AstraZeneca Fasenra (benralizumab) — Europe product sales ($M), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-fasenra-eu

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.